98%
921
2 minutes
20
Adjunctive thrombectomy during percutaneous coronary intervention (PCI) involves the mechanical removal of thrombus prior to balloon inflation and stent deployment .This has been a topic of ongoing debate in the management of ST-elevation myocardial infarction (STEMI), with prior studies yielding mixed outcomes. In this retrospective cohort study utilizing the TriNetX network, we analyzed data from hospitalized STEMI patients who underwent PCI between January 1, 2016, and December 31, 2023, stratifying them based on the use of adjunctive thrombectomy. Out of 50,104 patients, 1,967 (3.9%) underwent thrombectomy. After 1:1 propensity score matching to adjust for baseline differences, we found no significant differences in 30-day or 1-year all-cause mortality (HR: 1.212; 95% CI: 1.044 to 1.406) or stroke risk (HR: 0.865; 95% CI: 0.400 to 1.870) between the thrombectomy and nonthrombectomy groups. However, patients in the thrombectomy group experienced higher rates of heart failure (HF) readmissions and blood transfusion requirements at 1 year. These findings suggest that while adjunctive thrombectomy does not appear to increase the risk of mortality or stroke, its association with adverse clinical outcomes such as HF and transfusion needs indicates that its use should be reserved for carefully selected patients, particularly those with a high thrombus burden. Further prospective studies are necessary to clarify its role and determine the patient populations most likely to benefit.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.amjcard.2025.07.033 | DOI Listing |
Clin Neurol Neurosurg
September 2025
Department of Neurology, UTHealth Houston, Houston, TX, USA. Electronic address:
Background: Intra-arterial thrombolytics (IAT) as adjunctive therapy for large vessel occlusion acute ischemic stroke (LVO-AIS) after successful endovascular thrombectomy (EVT) may improve outcomes. This meta-analysis evaluates the efficacy and safety of IAT in this context.
Methods: We identified randomized controlled trials (RCTs) comparing IAT versus placebo or no IAT in LVO-AIS patients with successful recanalization post-EVT, including published studies and recent conference data.
Interv Neuroradiol
September 2025
Department of Neurology, University of Texas Rio Grande Valley, Valley Baptist Medical Center, Harlingen, TX, USA.
BackgroundThe safety and efficacy of intravenous thrombolysis (IVT) before mechanical thrombectomy (MT) in acute ischemic stroke remain uncertain.MethodsWe comprehensively searched PubMed, Embase, and the Cochrane Library from inception to May 30, 2025. Randomized controlled trials comparing IVT before MT versus MT alone in acute ischemic stroke were included.
View Article and Find Full Text PDFStroke
September 2025
Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY (A.M., D.G., J.F., J.M.).
Medium vessel occlusions represent a substantial proportion of patients with acute ischemic stroke. Recently presented randomized controlled trials, ESCAPE-MeVO (Endovascular Treatment to Improve Outcomes for Medium Vessel Occlusions), DISTAL (Endovascular Therapy Plus Best Medical Treatment [BMT] Versus BMT Alone for Medium Distal Vessel Occlusion Stroke), and DISCOUNT (Evaluation of Mechanical Thrombectomy in Acute Ischemic Stroke Related to a Distal Arterial Occlusion), did not demonstrate a clinical benefit of endovascular thrombectomy in distal and medium vessel occlusions, potentially generating uncertainty about optimal treatment strategies for medium vessel occlusions. Specifically, these results may lead clinicians to hesitate in performing endovascular thrombectomy for M2 occlusions, despite prior evidence indicating benefit in this subgroup.
View Article and Find Full Text PDFJ Neurointerv Surg
August 2025
Stroke Unit, Neurology, Hospital Vall d'Hebron, Barcelona, Spain.
Background: Endovascular thrombectomy (EVT) is the standard treatment for acute ischemic stroke (AIS) due to large vessel occlusion. However, many patients fail to achieve good outcomes, especially without first pass reperfusion. Intra-arterial thrombolytics such as recombinant tissue plasminogen activator (rtPA) and tirofiban have shown potential as adjunctive therapies.
View Article and Find Full Text PDFCureus
July 2025
Medicine and Surgery, King Edward Medical University, Lahore, PAK.
This systematic review evaluates the effectiveness and safety of adjunctive neuroprotective therapies administered in combination with reperfusion treatments, either intravenous (IV) thrombolysis, mechanical thrombectomy, or both, in adult patients with acute ischemic stroke (AIS). Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive search of four major databases was conducted with filters applied to include English-language randomized controlled trials (RCTs) published within the last five years. From an initial 622 records, 10 eligible RCTs were identified and analyzed.
View Article and Find Full Text PDF